Work

Hyperactive Factor IX Padua: A Game-Changer for Hemophilia Gene Therapy

Year: 2017
Type: article
Abstract: For the past 25 years, the development of gene therapy for hemophilia has fueled technological innovations and led to emerging insights that benefited the field at large.1,2 It was particularly encouraging that sustained expression of coagulation factor IX (FIX) was achieved after liver-directed gene therapy with adeno-associated viral vectors (AAVs) in patients with severe hemophilia B.3 Neverthless, the circulating FIX levels in that study—2%–5% range of normal—fell short of preventing spontaneous and trauma-induced bleeds.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2778505513
FWCI: 0.363
Cites: 17
Cited by: 26
Related to: 10